Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 33,732 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 33,732 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the sale, the executive vice president now owns 668,977 shares of the company’s stock, valued at $7,245,020.91. The trade was a 4.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The stock was sold at an average price of $10.73, for a total value of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The stock was sold at an average price of $11.42, for a total value of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total value of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $9.95 on Wednesday. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.88. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -7.77 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm’s 50-day simple moving average is $10.92 and its 200 day simple moving average is $8.66.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Alphatec in the 4th quarter valued at about $29,000. Comerica Bank lifted its position in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares in the last quarter. Quarry LP lifted its position in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after buying an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC bought a new position in shares of Alphatec during the 4th quarter worth approximately $50,000. Institutional investors own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Piper Sandler increased their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Finally, StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.